Category: Press Releases

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it has taken a significant step toward commercialization of its lead drug candidate by retaining the services of leading pharmaceutical branding agency, Addison Whitney. Addison Whitney, a Syneos Health company, will draw from its 28-year history to oversee the proprietary and non-proprietary drug naming process for Genprex’s lead drug candidate, currently known as Oncoprex™ immunogene therapy, for non-small cell lung cancer….

TUSC2 Immunogene Therapy Overcomes Resistance to Checkpoint Blockade

AUSTIN, Texas & CAMBRIDGE, Mass.— (April 8, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, reported that its collaborators from The University of Texas MD Anderson Cancer Center (“MD Anderson”) presented positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer in a poster presented at the American Association of Cancer Research Meeting 2019….

AUSTIN, Texas & CAMBRIDGE, Mass.— (April 1, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K with the United States Securities and Exchange Commission….

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced it will be presenting at the upcoming Cell & Gene Therapy Investor Day presented by the Alliance for Regenerative Medicine in New York City on March 21, 2019….

Genprex announced that it is continuing to grow its senior team with the hiring of Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing, effective immediately.

Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of John N. Bonfiglio, PhD, to the company’s Board of Directors. In recent years, Dr. Bonfiglio served as President and CEO of Oragenics, Inc.

Noble Capital Markets’ Fifteenth Annual Investor / Equity Conference

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 23, 2019– Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that its President and Chief Operating Officer, Julien Pham, MD, MPH, will deliver a presentation about the company’s unique, leading-edge gene therapies and will also participate in a discussion panel on the topic of “Novel Therapies at the Cutting Edge of Cancer Research” at NobleConXV – Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel in Fort Lauderdale, Florida….

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 3, 2019– Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare finance at the Hilton San Francisco Union Square….

Company Placing Priority on Investor Engagement with New Website, Email Updates

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 12, 2018– Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it will be increasing its investor relations efforts in 2019, spearheaded by the launch of an innovative corporate website with more robust investor resources, including the company’s presentations, stock charts and integrated quotes, SEC filings, news, media coverage, and tailored email newsletters, among other advanced communication tools….

Presentation Wed., Dec. 5, 2018, at 10:30 a.m. PST

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 3, 2018– Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that its Chairman and Chief Executive Officer, Rodney Varner, will present at the 11th annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel in Los Angeles, CA….